Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Pruritus Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Cholestasis Pruritus Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Bylvay, Livmarli, and Lynavoy for qualifying cholestatic pruritus indications under the Boeing commercial formulary.

    Policy Summary
    PayerPrime Therapeutics
    PolicyCholestasis Pruritus Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, applicable prerequisite therapy, safety review, specialist involvement, and supported quantity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Target drugs
    12 monthsApproval duration
    5Prerequisite agents
    60 tabletsLynavoy limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Hepatic exclusions

    Coverage Criteria

    Initial Therapy

    Initial therapy is covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • BOTH of the following

        • ONE of the following

          • The requested agent is Bylvay or Livmarli, and the patient has a diagnosis of Alagille syndrome with pruritus (medical records required).
          • ALL of the following

            • The requested agent is Bylvay or Livmarli, and the patient has a diagnosis of progressive familial intrahepatic cholestasis (PFIC) with pruritus (medical records required).
            • The patient does NOT have a diagnosis of PFIC2 with ABCB11 variants resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3).
        • ONE of the following

          • The requested agent is Lynavoy, and the patient is using it to treat cholestatic pruritus in primary biliary cholangitis (medical records required).
      • Another covered indication

        • The patient has another FDA-labeled indication for the requested agent and route of administration.
        • ONE of the following

          • The patient's age is within FDA labeling for the requested indication and requested agent.
          • There is support for using the requested agent for the patient's age and requested indication.
      • Compendia-supported indication

        • The patient has another indication supported in compendia for the requested agent and route of administration.
        • Compendia support is AHFS or DrugDex level 1 or 2a evidence.

    Prerequisite Therapy

    The patient must meet ALL of the following prerequisite-therapy requirements:

    ONE of the following

    • The patient tried and had an inadequate response to ONE prerequisite agent.
    • The patient has an intolerance or hypersensitivity to ONE prerequisite agent.
    • The patient has an FDA-labeled contraindication to ALL prerequisite agents.

    Initial Safety and Utilization Criteria

    After the applicable indication and prerequisite pathway is met, ALL of the following are required:

    ALL of the following

    • The patient has a serum bile acid concentration above the upper limit of normal (ULN).
    • ONE of the following

      • The patient has NOT had a liver transplant.
      • The patient has had a liver transplant and there is support for using the requested agent post liver transplant.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist or hepatologist), or the prescriber has consulted with such a specialist.

    Continuation or Renewal Therapy

    Continuation or renewal therapy is covered when ALL of the following are met:

    ALL of the following

    • The patient was previously approved for the requested agent through the plan's Prior Authorization process. Patients not previously approved require initial evaluation review.
    • The patient has had clinical benefit with the requested agent.
    • ONE of the following

      • The patient has NOT had a liver transplant.
      • The patient has had a liver transplant and there is support for using the requested agent post liver transplant.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist or hepatologist), or the prescriber has consulted with such a specialist.

    Quantity-Limit Exception

    A quantity-limit exception is covered when ALL of the following are met:

    ALL of the following

    • The requested quantity (dose) exceeds the program quantity limit.
    • ONE of the following

      • BOTH of the following

        • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • BOTH of the following

        • The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.

    The patient must NOT have decompensated cirrhosis or prior or active hepatic decompensation events, including variceal hemorrhage, ascites, or hepatic encephalopathy. This exclusion applies to both initial and renewal evaluations.

    If the requested agent is Livmarli, the patient must NOT have had surgical interruption of the enterohepatic circulation of bile acid. This criterion applies to both initial and renewal evaluations.

    The patient will NOT be using the requested agent in combination with another ileal bile acid transport (IBAT) inhibitor for the requested indication, including Bylvay, Livmarli, or Lynavoy. This criterion applies to both initial and renewal evaluations.

    Clinical Coding and Thresholds

    Serum bile acid concentration
    TestSerum bile acid concentration
    Required resultAbove the upper limit of normal (ULN)
    ApplicabilityRequired for applicable compendia-supported indications

    Provider Requirements and Decision Risks

    Prior Authorization

    Initial Prior Authorization Required

    Initial prior authorization is required for Bylvay (odevixibat), Livmarli (maralixibat), or Lynavoy (linerixibat). Approval requires a qualifying indication, required supporting documentation, and satisfaction of all applicable clinical criteria.

    • For Bylvay or Livmarli: Alagille syndrome with pruritus, or progressive familial intrahepatic cholestasis (PFIC) with pruritus, excluding PFIC2 with ABCB11 variants resulting in nonfunctional or complete absence of BSEP-3.
    • For Lynavoy: cholestatic pruritus in primary biliary cholangitis.
    • An alternative FDA-labeled indication or a compendia-supported indication may qualify when the requested agent and route are supported for the patient’s age and indication.
    Prior Authorization

    Renewal Prior Authorization

    Renewal prior authorization is required. Renewal approval requires that the patient was previously approved through the plan’s prior authorization process, has experienced clinical benefit, and continues to meet the applicable safety, indication, specialist, utilization, and quantity requirements.

    Policy Background

    This policy addresses pharmacologic treatment of cholestatic pruritus with ileal bile acid transport (IBAT) inhibitors. Covered target agents are Bylvay (odevixibat), Livmarli (maralixibat), and Lynavoy (linerixibat), with agent-specific pathways involving Alagille syndrome, progressive familial intrahepatic cholestasis, and cholestatic pruritus in primary biliary cholangitis. Authorization review includes hepatic safety, transplant status, serum bile acid results when applicable, specialist involvement, avoidance of concurrent IBAT inhibitor therapy, and FDA-labeled or compendia-supported dosing.

    Key Definitions

    IBAT inhibitor
    Full termIleal bile acid transport inhibitor
    Covered examplesBylvay, Livmarli, and Lynavoy
    Combination useThe requested agent must not be used with another IBAT inhibitor for the requested indication
    PFIC
    Full termProgressive familial intrahepatic cholestasis
    Covered disease pathwayPFIC with pruritus is a qualifying pathway for Bylvay or Livmarli
    PFIC2 restrictionPFIC2 with ABCB11 variants resulting in non-functional or complete absence of BSEP-3 is excluded from the applicable Bylvay or Livmarli pathway

    Initial Therapy

    Initial Therapy

    Initial therapy requires a qualifying indication, the applicable prerequisite-agent pathway, and all applicable safety and utilization requirements.

    Initial therapy

    • Qualifying indication

      • Bylvay or Livmarli labeled disease pathway

        • Alagille or PFIC

          • The requested agent is Bylvay or Livmarli and the patient has Alagille syndrome with pruritus.
          • The requested agent is Bylvay or Livmarli and the patient has PFIC with pruritus, without PFIC2 with ABCB11 variants resulting in non-functional or complete absence of bile salt export pump protein BSEP-3.

    Continuation and Renewal Therapy

    Continuation Therapy

    Renewal requires all of the following.

    Continuation therapy: The patient was previously approved for the requested agent through the plan's prior authorization process, has experienced clinical benefit, continues to meet hepatic safety requirements, satisfies applicable Livmarli and transplant requirements, has specialist involvement, will not use another IBAT inhibitor concurrently, has no FDA-labeled contraindication, and has a quantity within FDA-label or compendia support.

    Patients without prior plan approval require initial evaluation review. Approval length is 12 months.

    Prerequisite-Agent Step Therapy

    StepPrerequisite agentRequirement or exception
    1CholestyramineTry and demonstrate an inadequate response; alternatively, document intolerance or hypersensitivity to this agent, or an FDA-labeled contraindication to all prerequisite agents.
    1NaltrexoneTry and demonstrate an inadequate response; alternatively, document intolerance or hypersensitivity to this agent, or an FDA-labeled contraindication to all prerequisite agents.
    1RifampicinTry and demonstrate an inadequate response; alternatively, document intolerance or hypersensitivity to this agent, or an FDA-labeled contraindication to all prerequisite agents.
    1SertralineTry and demonstrate an inadequate response; alternatively, document intolerance or hypersensitivity to this agent, or an FDA-labeled contraindication to all prerequisite agents.
    1UrsodiolTry and demonstrate an inadequate response; alternatively, document intolerance or hypersensitivity to this agent, or an FDA-labeled contraindication to all prerequisite agents.

    Program Quantity Limits

    Lynavoy quantity limit
    AgentLynavoy (linerixibat)
    Strength and dosage form40 mg tablets
    Program limit60 tablets per 30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyCholestasis Pruritus Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing a qualifying indication, applicable prerequisite therapy, safety review, specialist involvement, and supported quantity.
    SourceLink
    On This Page
    Coverage CriteriaClinical Coding and ThresholdsProvider Requirements and Decision RisksPolicy BackgroundKey DefinitionsInitial TherapyContinuation and Renewal TherapyPrerequisite-Agent Step TherapyProgram Quantity Limits
    The patient does NOT have any FDA-labeled contraindications to the requested agent.
  1. The requested quantity (dose) is within FDA labeling or supported in compendia for the requested indication.
  2. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  3. The requested quantity (dose) is within FDA labeling or supported in compendia for the requested indication.
  4. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
  5. BOTH of the following

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
    • Patients not previously approved through the plan’s prior authorization process require initial evaluation review.
    • The patient must continue to meet hepatic safety, liver-transplant, specialist, contraindication, concurrent-IBAT-inhibitor, and quantity criteria.
    Note

    Approval Duration

    Initial and renewal approvals are each issued for 12 months. If a quantity limit applies, the quantity-limit criteria must also be satisfied for the approval period.

    • Initial approval duration: 12 months.
    • Renewal approval duration: 12 months.
    Step Therapy

    Prerequisite-Agent Requirement

    The patient must have tried and had an inadequate response to one prerequisite agent, or have an intolerance or hypersensitivity to one prerequisite agent. An FDA-labeled contraindication to all prerequisite agents also satisfies the prerequisite pathway.

    • Prerequisite agents: cholestyramine, naltrexone, rifampicin, sertraline, or ursodiol.
    • The prerequisite pathway applies to the qualifying indication unless an applicable policy criterion provides another supported indication pathway.
    Documentation Required

    Diagnosis Documentation

    Submit medical records documenting the qualifying diagnosis and related pruritus. Documentation must support the requested agent’s applicable indication.

    • Bylvay or Livmarli: Alagille syndrome with pruritus, or PFIC with pruritus; PFIC2 with ABCB11 variants causing nonfunctional or absent BSEP-3 is excluded.
    • Lynavoy: cholestatic pruritus associated with primary biliary cholangitis.
    • For another FDA-labeled or compendia-supported indication, submit records supporting that indication, route, and patient age.
    Documentation Required

    Prerequisite Therapy Documentation

    Document the prerequisite-agent outcome supporting the request. The records must show an inadequate response, intolerance, hypersensitivity, or an FDA-labeled contraindication as applicable.

    • Identify the prerequisite agent(s) tried and the treatment outcome.
    • For intolerance or hypersensitivity, document the relevant reaction.
    • For contraindication, document the FDA-labeled contraindication to all prerequisite agents.

    Unsupported block type: documentation

    Documentation Required

    Serum Bile Acid Result

    For applicable indications, submit a serum bile acid result showing a concentration above the upper limit of normal (ULN).

    • Include the laboratory result and reference range or ULN used for interpretation.
    Documentation Required

    Specialist Involvement

    The prescriber must be a specialist in the area of the patient’s diagnosis, such as a gastroenterologist or hepatologist, or must document consultation with an appropriate specialist.

    • Submit the prescriber’s specialty or documentation of specialist consultation.
    • Specialist involvement applies to both initial and renewal evaluation.
    Documentation Required

    Renewal Documentation

    Renewal requests must document prior plan approval, treatment experience, and continued support for therapy. Include evidence of clinical benefit and confirmation that all renewal safety and utilization criteria remain satisfied.

    • Document the prior approval through the plan’s prior authorization process.
    • Document clinical benefit with the requested agent.
    • Update diagnosis, specialist involvement, liver-transplant support if applicable, contraindication review, concurrent-IBAT-inhibitor review, and requested quantity.
    Billing Rule

    Quantity-Limit Exception Documentation

    If the requested quantity exceeds the program quantity limit, submit clinical support for the excess quantity and explain why the need cannot be met with a lower quantity of a higher strength when that alternative is applicable.

    • If there is no maximum FDA-labeled dose, provide support for the higher dose.
    • If the quantity does not exceed the maximum FDA-labeled dose, explain why it cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    • If the quantity exceeds the maximum FDA-labeled dose, provide support for therapy at the higher dose.
    Denial Risk

    No Qualifying Indication or Prerequisite Therapy

    The request may be denied when the patient lacks a qualifying diagnosis or supported indication, or when the required prerequisite-agent pathway is not met. Missing medical records, missing indication or route support, or failure to demonstrate an inadequate response, intolerance, hypersensitivity, or contraindication may prevent approval.

    • The requested agent must be used for a qualifying FDA-labeled or compendia-supported indication.
    • The required prerequisite-agent criteria must be documented unless an applicable exception is satisfied.
    Denial Risk

    Hepatic Safety Exclusion

    The request may be denied if the patient has decompensated cirrhosis, prior or active hepatic decompensation events, or an FDA-labeled contraindication to the requested agent.

    • Examples of hepatic decompensation events include variceal hemorrhage, ascites, and hepatic encephalopathy.
    • The absence of applicable hepatic safety exclusions and FDA-labeled contraindications must be confirmed for initial and renewal requests.
    Denial Risk

    Livmarli Surgical Contraindication

    For Livmarli, approval may be denied when the patient has had surgical interruption of the enterohepatic circulation of bile acid.

    • Confirm this exclusion during both initial and renewal review.
    Denial Risk

    Concurrent IBAT Inhibitor Use

    The patient must not use the requested agent in combination with another ileal bile acid transport (IBAT) inhibitor for the requested indication. Concurrent use may result in denial.

    • IBAT inhibitors include Bylvay, Livmarli, and Lynavoy.
    • Confirm that the requested indication will not involve concurrent IBAT inhibitor therapy.
    Denial Risk

    Unsupported Quantity-Limit Exception

    A quantity-limit exception may be denied when the requested quantity exceeds the program limit and the submission does not provide the required clinical support or does not explain why a lower quantity of a higher strength cannot be used.

    • Support must address the applicable FDA maximum dose and the rationale for the requested quantity.
    • The requested quantity must otherwise be within FDA labeling or supported in compendia for the requested indication.
    BSEP
    Full termBile salt export pump protein
    Relevant conditionPFIC2 with ABCB11 variants resulting in non-functional or complete absence of BSEP-3
    Coverage relevanceThis PFIC2/BSEP-3 condition is excluded from the applicable Bylvay or Livmarli pathway
    Lynavoy labeled disease pathway: The requested agent is Lynavoy and is being used to treat cholestatic pruritus in primary biliary cholangitis.

    Medical records are required.

  6. Other FDA-labeled indication: The patient has another FDA-labeled indication for the requested agent and route of administration, and the patient's age is within FDA labeling or there is support for use at the patient's age.
  7. Compendia-supported indication: The patient has another indication supported in compendia for the requested agent and route of administration, has a serum bile acid concentration above the upper limit of normal, and meets the applicable safety, transplant, specialist, interaction, contraindication, and quantity requirements.Serum bile acid concentration above the ULN

    Compendia support may be based on AHFS or DrugDex level 1 or 2a evidence.

  8. Prerequisite-agent pathway: The patient has tried and had an inadequate response to one prerequisite agent; has an intolerance or hypersensitivity to one prerequisite agent; or has an FDA-labeled contraindication to all prerequisite agents.

    Prerequisite agents are cholestyramine, naltrexone, rifampicin, sertraline, and ursodiol.

  9. Applicable safety and utilization requirements: The patient does not have decompensated cirrhosis or prior or active hepatic decompensation events; satisfies the applicable Livmarli, transplant, specialist, interaction, contraindication, and quantity requirements; and meets any applicable serum bile acid requirement.